Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies

Calon, Frédéric; Cole, Greg M.

doi:10.1016/j.plefa.2007.10.019

Cited by 252 publications

(158 citation statements)

References 62 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…For example, alterations in lipid metabolism that result in low circulating docosahexaenoic acid (DHA) levels may increase the risk of developing AD. 26 The disturbances in lipid metabolism may lead to inappropriate cleavage of App and poor functioning of other susceptible proteins such as glucose transporters. The alterations may be evident as hypometabolism, accumulation of amyloid, and the generation of reactive oxygen species.…”

Section: Glucose Metabolism In Admentioning

confidence: 99%

Ketone Bodies as a Therapeutic for Alzheimer's Disease

Henderson¹

2008

Neurotherapeutics

301

120

View full text Add to dashboard Cite

Summary: An early feature of Alzheimer's disease (AD) is region-specific declines in brain glucose metabolism. Unlike other tissues in the body, the brain does not efficiently metabolize fats; hence the adult human brain relies almost exclusively on glucose as an energy substrate. Therefore, inhibition of glucose metabolism can have profound effects on brain function. The hypometabolism seen in AD has recently attracted attention as a possible target for intervention in the disease process. One promising approach is to supplement the normal glucose supply of the brain with ketone bodies (KB), which include acetoacetate, ␤-hydroxybutyrate, and acetone. KB are normally produced from fat stores when glucose supplies are limited, such as during prolonged fasting. KB have been induced both by direct infusion and by the administration of a high-fat, low-carbohydrate, low-protein, ketogenic diets. Both approaches have demonstrated efficacy in animal models of neurodegenerative disorders and in human clinical trials, including AD trials. Much of the benefit of KB can be attributed to their ability to increase mitochondrial efficiency and supplement the brain's normal reliance on glucose. Research into the therapeutic potential of KB and ketosis represents a promising new area of AD research.

show abstract

Section: Glucose Metabolism In Admentioning

confidence: 99%

Ketone Bodies as a Therapeutic for Alzheimer's Disease

Henderson¹

2008

Neurotherapeutics

301

120

View full text Add to dashboard Cite

show abstract

“…The use of a mouse model of Alzheimer's disease, the Tg2576 mouse, has demonstrated that a dietary supply of DHA leads to a reduction in the formation of amyloid plaques. However, the administration of dietary supplements containing DHA to patients with Alzheimer's disease or mild cognitive impairment has not yielded conclusive results (Calon and Cole, 2007).…”

Section: Consequences Of the Decrease In N-3 Pufas On Age-related Neumentioning

confidence: 99%

Neuroinflammation and aging: influence of dietary n-3 polyunsaturated fatty acid

Layé

Delpech

Smedt-Peyrusse

et al. 2011

OCL

View full text Add to dashboard Cite

“…Several epidemiological, clinical and basic-experimental studies have demonstrated the beneficial effects of n-3 LCPUFA against various diseases, among which; cardiovascular disease (Hamer and Steptoe., 2006), some cancers (Gillet et al, 2011), inflammatory diseases such as rheumatoid arthritis (Kremer et al, 1990) and asthma (Yokoyama et al, 2000), neurological disorders such as schizophrenia (Laugharne et al, 1996), depression (Hibbeln & Salem, 1995), migraine (Wagner & Nootbaar-Wagner, 1997) and neurodegenerative diseases such as Alzheimer's disease (Morley & Banks, 2010), Multiple sclerosis (Mehta et al, 2009) and Parkinson's disease (Calon & Cole, 2007). The evidence of the beneficial effect of DHA has been clearly demonstrated mainly in neurodegenerative diseases.…”

Section: Dha and Neurodegenerative Diseasesmentioning

confidence: 99%